Many of the symptoms of Alzheimer’s disease are similar to those of other conditions.
No two cases of Alzheimer's disease are ever the same because different people react in different ways to the condition. However, generally, there are three stages to the condition:
Alzheimer’s disease tends to ‘creep up’ on you, so you may not notice the symptoms immediately. The symptoms progress slowly over a seven- to ten-year period. However, the rate at which they progress will differ for each individual.
The three stages of Alzheimer’s disease are described below.
Common symptoms of mild Alzheimer's disease include:
These symptoms are a result of a gradual loss of brain function. The first section of the brain to start deteriorating is often the part that controls the memory and speech functions.
As Alzheimer's disease develops into the moderate stage, it can also cause:
During the moderate stage, you may have difficulty remembering very recent things. Problems with language and speech could also start to develop at this stage. This can make you feel frustrated and depressed, leading to mood swings.
Someone with severe Alzheimer's disease may seem very disorientated and show signs of major confusion.
This is also the stage where people are most likely to experience hallucinations and delusions. They may think that they can smell, see or hear things that are not there, or believe that someone has stolen from them or attacked them when they have not. This can be distressing for friends and family, as well as for the person with Alzheimer's disease.
The hallucinations and delusions are often worse at night, and the person with Alzheimer's disease may start to become violent, demanding and suspicious of those around them.
As Alzheimer's disease becomes severe, it can also cause a number of other symptoms such as:
During the severe stage of Alzheimer's disease, people often start to neglect their personal hygiene. It is at this stage that most people with the condition will need to have full-time care because they will be able to do very little on their own.
Alzheimer's disease affects a person's ability to look after themselves when they are unwell, so another health condition can develop rapidly if left untreated. A person with Alzheimer's may also be unable to tell someone if they feel unwell or uncomfortable.
Alzheimer's disease can shorten life-expectancy. This is often caused by those affected developing another condition, such as pneumonia (inflammation of the lungs), as a result of having Alzheimer's disease. In many cases, Alzheimer's disease may not be the actual cause of death, but it can be a contributing factor.
]]>
You should visit your GP if you think that you may have Alzheimer’s disease. They will want to know about any new or worsening problems that you have noticed. For example:
Alzheimer's disease can be a difficult condition to diagnose because the symptoms can be similar to those of other health conditions. For example, the symptoms of Alzheimer’s disease may be confused with:
There is no basic test for diagnosing Alzheimer's disease, so the diagnosis is usually based on ruling out other conditions. You may have blood tests and a physical examination to rule out other medical conditions that could be causing your symptoms.
If your GP suspects Alzheimer's disease, you may also be given a brain scan, which will look for changes in your brain. This could be:
See Dementia - diagnosis for more information about the different tests that you might have.
Your GP may refer you to a specialist to help with the diagnosis. For example, you may be referred to:
Your specialist may carry out some tests to assess your memory and thinking skills. One example is explained below.
The Mini Mental State Examination (MMSE) is a test that is sometimes used to assess the severity of Alzheimer’s disease. MMSE cannot provide a diagnosis of Alzheimer’s disease on its own, but it may help determine the treatment you should receive.
MMSE can be used to assess a number of different mental abilities including:
The MMSE test consists of a series of tasks such as:
The maximum score for the MMSE is 30. A score of 30 is classed as normal, but any less than 30 and you may have Alzheimer’s disease. The lower your score, the more severe your condition is. Alzheimer’s disease is classified as follows:
MMSE might not be the most suitable way of assessing the severity of your Alzheimer’s disease, in which case it may not be used, or it may be used alongside other tests. Factors that may affect your MMSE score will be taken into consideration, for example:
It may take several appointments with your GP and specialist before a diagnosis of Alzheimer’s disease can be confirmed.
If you are diagnosed with Alzheimer’s disease, your GP or specialist may recommend that the diagnosis is shared with your family or your carers. However, this will only be done with your permission.
]]>
There is currently no cure for Alzheimer's disease, but there are various medications that are available on prescription that can help delay the condition’s development.
Treatment for Alzheimer’s disease also involves creating a care plan. This identifies the type of assistance that you might need, and focuses on ways of providing this support.
Medication that may be prescribed for Alzheimer’s disease includes:
Whether these medications are used will depend on the severity of your Alzheimer’s disease. This will be assessed with tests, such as the Mini Mental State Examination (MMSE). See Alzheimer’s disease - diagnosis for an explanation of the MMSE.
In the first instance, these medications can only be prescribed by a specialist who has experience in treating dementia, such as:
After this, your GP may be able to repeat your prescription, and you may be monitored by both your specialist and your GP. Your MMSE score will be reviewed every six months.
If you have moderate Alzheimer's disease (if your MMSE score is between 10 and 20), the National Institute for Health and Clinical Excellence (NICE) recommends that you are prescribed:
The healthcare professionals treating you will decide which of these medicines is the most appropriate treatment for you.
Donepezil, galantamine and rivastigmine are known as acetylcholinesterase inhibitors. They work by preventing a chemical breakdown in the brain.
When nerve cells are damaged by brain deterioration they release a chemical called acetylcholine. By preventing the breakdown of acetylcholine, brain deterioration is also slowed.
In the UK, memantine is licensed to treat people with moderate to severe Alzheimer’s disease (an MMSE score of 20 or less). However, NICE does not recommend the use of memantine in people with moderately severe to severe Alzheimer’s (an MMSE score of 14 or less).
You may be prescribed memantine as part of a clinical trial (a type of medical research that tests one type of treatment against another). If you are currently taking memantine, you may continue to take it until you, your carers and your specialist consider it appropriate to stop.
Memantine works by blocking chemicals that are often released in large amounts in people with Alzheimer's disease. These chemicals can damage nerve cells and prevent messages moving to and from the brain.
Donepezil, galantamine and rivastigmine (acetylcholinesterase inhibitors) can cause side effects including:
For more information about the possible side effects of a particular medication, refer to the patient information leaflet that comes with your medication, or see Medicines information.
Alzheimer’s disease is the most common form of dementia. Dementia is a syndrome (a group of symptoms) that is associated with an ongoing decline in mental abilities. The treatment for Alzheimer’s disease will follow the same pattern as treatment for dementia.
If you have been diagnosed with any other conditions as well as Alzheimer’s disease, for example, depression or incontinence (when you unintentionally pass urine or stools), these may be treated separately.
If you have been diagnosed with Alzheimer's disease, your future health and social care needs will be assessed and a care plan will be drawn up. This will be coordinated by:
As part of your care assessment your functional capacity will be assessed. This involves identifying areas where you may need some assistance with your day-to-day activities. For example, areas that may be assessed include:
Following the care assessment, a care plan can be drawn up to arrange support for any areas where you may need to have some help. The kind of care that you will receive may depend on what is available from your local primary care trust (PCT).
The healthcare professionals who are treating you will aim to keep you living as independently as possible. Support can be provided in many different ways. For example:
See the Health A-Z topic about Dementia - treatment for more information.
If you are concerned about any issues to do with your care, or if you are caring for someone with Alzheimer’s disease, you can find information and advice on the Carers Direct section of the website. This includes advice about:
Alzheimer’s disease is caused by parts of the brain wasting away, which damages the structure of the brain and how it works. The medical name for wasting away is atrophy.
The atrophy mainly affects the cerebral cortex, which is the layer of grey matter that covers the brain. Grey matter is responsible for processing thoughts.
As the cerebral cortex wastes away, clumps of protein, known as ‘plaques’ and ‘tangles’, start to form in the brain. The plaques and tangles start to destroy more brain cells, which makes the condition worse. They also affect the neurotransmitters (chemicals that carry messages to and from the brain).
It is still unknown what actually causes the deterioration of brain cells, although there are several factors that are known to affect the development of Alzheimer's disease. These are described in more detail below.
Age is the greatest factor in the development of Alzheimer's disease. The likelihood of developing the condition doubles every five years after you reach 65 years of age. However, it is not just older people who are at risk of developing Alzheimer's disease.
Alzheimer's disease can also be inherited (run in the family), although the risk is only marginally higher than that of someone who has no family history of the condition.
In cases where Alzheimer's disease is inherited, the symptoms may start to develop at a relatively early age (between 35 and 60 years of age).
People with Down's syndrome (a genetic disorder that affects physical appearance, as well as the ability to learn and develop mentally) are at a higher risk of developing Alzheimer's disease.
This is because people with Down's syndrome have an extra copy of chromosome 21, which contains a protein found in the brain of those with Alzheimer's disease. Therefore, people with Down's syndrome have a higher-than-average amount of this protein, which could contribute to developing Alzheimer's disease.
People who have had a severe head injury, or severe whiplash (a neck injury caused by a sudden movement of the head forwards, backwards or sideways), have been found to have a higher risk of developing Alzheimer's disease.
Aluminium is a naturally occurring substance found in food and plants. It is also added to products, such as pans, packaging and medicines. The body only absorbs a minimal amount of aluminium, which is usually passed out of the body in urine.
It has been suggested that aluminium could be a possible cause of Alzheimer's disease because research found that the plaques and tangles in the brain contain aluminium. However, further research has failed to prove a link between aluminium and Alzheimer's disease.
]]>As the cause of Alzheimer’s disease is still unknown, there is no way to prevent the condition. However, there are some steps that you can take to try to delay the onset of dementia. You should:
Research into Alzheimer’s disease is continuing, and as more is revealed about the condition, other ways to treat or prevent it may be found. However, research does not always produce successful results.
The National Institute for Health and Clinical Excellence (NICE) has recommended that the following should not be used to try to prevent dementia: